

## **SUPPLEMENTAL FIGURE LEGENDS**

**Supplemental Figure 1.** Immunohistochemistry for AR in BT549 cells cultured in attached or forced suspension culture conditions. Representative images; scale bar, 50  $\mu\text{m}$ .

**Supplemental Figure 2.** Limiting dilution tumor size. At the end of study final tumor viability and volumes were measured in mice with palpable tumors (104, 105, 106 cells per injection). Mean  $\pm$  SD.

**Supplemental Figure 3.** Paclitaxel and enzalutamide combination treatment. **A**, proliferation assay of SUM159PT-TGL cells treated 3 days with vehicle control (0.1% DMSO), Enzalutamide (Enza), and/or paclitaxel (Pac) in vitro. **B**, schematic of mouse injection, tumor matching, and treatment for Pac and Enza combination in vivo experiment. **C**, matching of tumor volume by caliper measurements and luciferase activity by total flux. Mean  $\pm$  SD; \*\*  $p < 0.01$ , \*\*\*  $p < 0.001$ .